Overall, immune checkpoint expression may be dysregulated in the HCC microenvironment, and cancer immunotherapy based on CTLA-4, PDCD1 and PD-L1 inhibitors may achieve antitumor therapeutic effects by improving Treg cell-mediated immune responses. This evidence concerns the gene PDCD1 and cancer.